Monophosphoryl lipid A: A novel agent for inducing pharmacologic myocardial preconditioning

Journal of Thrombosis and Thrombolysis

Volumn 3, Issue 3, 1996, Pages 225-237

  Elliott, Gary T ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Ischemia; Monophosphoryl lipid A; Preconditioning; Reperfusion

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE KINASE; ADENOSINE RECEPTOR; ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; CALCIUM; CHOLINERGIC RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; NITRIC OXIDE; PHOSPHORYL LIPID A; POTASSIUM CHANNEL; PROTEIN KINASE C;

ANAEROBIC METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CALCIUM CELL LEVEL; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DOG; ENZYME ACTIVATION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; INTRAVENOUS DRUG ADMINISTRATION; MYOFILAMENT; NONHUMAN; PRIORITY JOURNAL; RABBIT; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; STUNNED HEART MUSCLE;

EID: 0029736754     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00181665     Document Type: Review

References (86)

1. Ambrosio G, Flaherty JT, Duilio C, et al. Oxygen radicals generated at reflow induce peroxidation of membrane lipids in reperfused hearts. J Clin Invest 1991;87:2056-2066.
2. Steenbergen C, Murphy E, Levy L, London RE. Evaluation of cytosolic free calcium concentration early in myocardial ischemia in perfused rat heart. Circ Res 1987;60: 700-707.
3. Lee JA, Allen DG. Changes in intracellular free calcium concentrations during long exposures to simulated ischemia in isolated mammalian ventricular muscle. Circ Res 1992; 71:58-69.
4. Lucchesi BR, Mullane KM. Leukocytes and ischemia-induced myocardial injury. Ann Rev Pharmacol Toxicol 1986;26:201-224.
5. Rowe GT, Eaton LR, Hess ML. Neutrophil-derived, oxygen free radical-mediated cardiovascular dysfunction. J Mol Cell Cardiol 1984;16:1075-1079.
6. Godin DV, Bhimji S. Effects of allopurinol on myocardial ischemic injury induced by coronary artery ligation and reperfusion. Biochem Pharmacol 1987;36:2101-2107.
7. Godin DV, Bhimji S. Effects of allopurinol pretreatment on myocardial ultrastructure and arrhythmias following coronary artery occlusion and reperfusion. Virchows Arch B Cell Pathol 1986;52:327-341.
8. Jolly SR, Kane WJ, Bailie MB, Abrams GD, Lucchesi BR. Canine myocardial reperfusion injury: Its reduction by the combined administration of superoxide dismutase and catalase. Circ Res 1984;54:277-285.
9. Dreyer WJ, Michael LH, West MS et al. Neutrophil accumulation in ischemic canine myocardium. Insights into time course, distribution and mechanism of localization during early reperfusion. Circulation 1991;84:400-411.
10. Tamiya Y, Yamamoto N, Uebe T. Protective effect of monoclonal antibodies against LFA-1 and ICAM-1 on myocardial reperfusion injury following global ischemia in rat hearts. Immunopharmacology 1995;29:53-63.
11. +2 overload inhibitor, on myocardial injury in ischemic, reperfused porcine hearts. J. Cardiovasc Pharmacol 1995;25:163-167.
12. Jones DR, Abbott AE, Hill RC, Beamer KC, Gustafson RA, Murray GF. Preservation of adenosine 5′-triphosphate and mitochondrial function during hypercalcemic reperfusion using verapamil cardioplegia. Chest 1995;107:307-310.
13. Bugge E, Ytrehas K. Inhibition of sodium-hydrogen exchange reduces infarct size in the isolated rat heart - a protective additive to ischemic preconditioning. Cardiovasc Res 1995;29:269-274.
14. Droy-Lefaix MT, Drouet Y, Gerard G, Hasford D, Braquet P. Superoxide dismutase (SOD) and the PAF-antagonist (Bn52021) reduce small intestinal damage induced by ischemia-reperfusion. Free Radic Res Commun 1991;12-13: 725-735.
15. Murray CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-1136.
16. Li GC, Vasquez JA, Gallagher KP, Lucchesi BR. Myocardial protection with preconditioning. Circulation 1990;82: 609-619.
17. Ovize M, Kloner RA, Hale SL, Przyklenk K. Coronary cyclic flow variations "preconditions" ischemic myocardium. Circulation 1992;85:779-789.
18. Parratt JR. Protection of the heart by ischemic-preconditioning: Mechanisms and possibilities for pharmacologic exploitation. Trends Pharmacol Sci 1994;15:19-25.
19. Marber MS, Latchman DS, Walker JM, Yellon DM. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 1993;88:1264-1272.
20. 1 adenosine receptors in rabbit heart. Circulation 1991;84:350-356.
21. Thornton JD, Thornton CS, Downey JM. Effect of adenosine receptor blockage: Preventing protective preconditioning depends on time of initiation. Am J Physiol 1993; 265:H504-H505.
22. Kitakaze M, Hori M, Morioka T, et al. Alpha-adrenoceptor activation mediates the infarct size-limiting effect of ischemic preconditioning through augumentation of 5′-nucleotidase activity. J Clin Invest 1994;93:2197-2205.
23. Ytehus K, Liu Y, Downey JM. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol 1994;266:H1145-H1152.
24. Splechly-Dick ME, Mocanu MM, Yellon DM. Protein kinase C: Its role in ischemic preconditioning in the rat. Circ Res 1994;75:586-590.
25. 1 selective adenosine analogs protects the heart against infarction. Circulation 1992;85:659-665.
26. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channel prevents myocardial preconditioning in dogs. Circ Res 1992;70:223-233.
27. + channel in mediating the effects of acetylcholine to mimic preconditioning in dogs. Circ Res 1993;73:1193-1201.
28. Gross G, Pieper G, Farber NL, Warltier D, Hardman H. Effects of nicorandil on coronary circulation and myocardial ischemia. Am J Cardiol 1989;63:11J.
29. Yao Z, Gross GJ. The ATP-dependent potassium channel: An endogenous cardioprotective mechanism. J Cardiovasc Pharmacol 1994;24(Suppl 4):S28-S34.
30. Rohmann S, Weygandt H, Schelling P, Kie Soli L, Verdouw PD, Lues I. Involvement of ATP-sensitive potassium channels in preconditioning protection. Basic Res Cardiol 1994; 89:563-576.
31. + channels to A1 receptors by G proteins in rat ventricular myocytes. Am J Physiol 1990;259 (Heart Circ Physiol 28):H820-H826.
32. Wall TM, Sheehy R, Hartman JC. Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther 1994; 270:681-689.
33. Hartman JC, Kurc GM, Hullinger TG, Wall TM, Sheehy RM, Shebuski RJ. Inhibition of nitric oxide synthase prevents myocardial protection by ramiprilat. J Pharmacol Exp Ther 1994;270:1071-1076.
34. Gato M, Lui Y, Yang X-M, Ardell JL, Cohen MV, Downey JM. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res 1995;77:611-621.
35. Baxter GF, Marber MS, Patel VC, Yellon D.M. A 'second window of protection' 24-hours after ischemic preconditioning may be dependent upon adenosine receptor activation. Circulation 1993;88:I101.
36. 1 receptors. Circulation 1992;86:1310-1316.
37. Grover GJ, Dzwonczyk S, Parham CS, Sleph PG. The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in isolated perfused rat hearts and anesthetized dogs. Cardiovasc Drug Ther 1990;4:465-474.
38. ATP channel opener bimakalim on coronary blood flow, monophasic action potential duration and infarct size in dogs. Circulation 1994;89: 1769-1775.
39. Lin Y, Ytrehus K, Downey JM. Evidence that translocation of protein kinase C is a key event during ischemic preconditioning of rabbit myocardium. J Mol Cell Cardiol 1994;26: 661-668.
40. Armstrong S, Ganote CE. Preconditioning of isolated rabbit cardiomyocytes: Effects of glycolytic blockade, phorbol esters, and ischemia. Cardiovasc Res 1994;28:1700-1706.
41. Nakanishi K, Vinten-Johansen J, Lefer DJ, et al. Intracoronary L-arginine during reperfusion improves endothelial function and reduces infarct size. Am J Physiol 1992;263 (Heart Circ Physiol 32):H1650-H1658.
42. Brown JM, Grosso MA, Terada LS, et al. Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat hearts. Proc Natl Acad Sci USA 1989;86:2516-2520.
43. Bensard DD, Brown JM, Anderson BO, et al. Induction of endogenous tissue antioxidant enzyme activity attenuates myocardial reperfusion injury. J Surg Res 1990;48:1-6.
44. Nelson SK, Wong GH, McCord JM. Leukemia inhibitory factor and tumor necrosis factor induce manganese superoxide dismutase and protect rabbit hearts from reperfusion injury. J Moll Cell Cardiol 1995;27:223-229.
45. Berg JT, Allison RC, Taylor AE. Endotoxin extends survival of adult mice in hyperoxia. Proc Soc Exp Biol Med 1990;193:167-170.
46. Takayama K, Ribi E, Cantrell JL. Isolation of a non-toxic lipid A fraction containing tumor regression activity. Cancer Res 1981;41:2654-2657.
47. Qureshi N, Takayama K, Ribi E. Purification and structural determination of nontoxic lipid A obtained from lipopolysaccharide of Salmonella typhimurium. J Biol Chem 1982;257: 11808-11815.
48. Takayama K, Qureshi N, Ribi E, Cantrell JL. Separation and characterization of toxic and nontoxic forms of lipid A's. Rev Infect Dis 1984;6:439-443.
49. Ribi E. Beneficial modification of the endotoxin molecule. J Biol Resp Modif 1984;3:1-9.
50. Astiz ME, Rackow EC, Still JG, et al. Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: A prospective, double-blind, randomized, controlled trial. Crit Care Med 1995;23:9-17.
51. Yao Z, Auchampach JA, Pieper GM, Gross G. Cardioprotective effects of monophosphoryl lipid A, a novel endotoxin analogue, in the dog. Cardiovasc Res 1993;27:832-838.
52. Yao Z, Rasmussen JL, Hirt JL, Mei DA, Pieper GM, Gross GJ. Effects of monophosphoryl lipid A on myocardial ischemia/reperfusion injury in dogs. J Cardiovasc Pharmacol 1993;22:653-663.
53. + channels mediate the cardioprotective effect of monophosphoryl lipid A. Circulation, 1995;92:I-388.
54. Przyklenk K, Zhao L, Kloner RA, Elliott GT. Monophosphoryl lipid A (MLA) is a "preconditioning-mimetic" in the canine model. Circulation 1995;92:I-388.
55. Yosida K-I, Maaieh MM, Shipley JB, et al. Monophosphoryl lipid A induces pharmacologic 'preconditioning' in rabbit hearts without concomitant expression of 70-kilodalton heat shock protein. Mol Cell Biochem 1996;156:1-8.
56. Yoshida K-I, Maaieh MM, Shipley JB, et al. Monophosphoryl lipid A induces pharmacologic "preconditioning" in rabbit hearts without concomitant expression of 70-kilodalton heat shock protein. J Mol Cell Cardiol 1995;27: A164.
57. Baxter GP, Goodwin RW, Wright MJ, Kerac M, Heads RJ, Yellon DM. Myocardial protection after monophosphoryl lipid A: Studies of delayed anti-ischemic properties in the rabbit heart. British J Pharmacol 1996;117:1685-1692.
58. Baxter GF, Goodwin RW, Wright MJ, Kerac M, Yellon DM. Delayed myocardial protection following monophosphoryl lipid A treatment in the rabbit is not associated with elevation of 70-kDa stress protein. Circulation 1995;92: 1-654.
59. Yao Z, Elliott GT, Gross GJ. Monophosphoryl lipid A (MLA) preserves myocardial contractile function following multiple, brief periods of coronary occlusion in dogs. Pharmacology 1995;51:152-159.
60. Abd-Elfattah AS, Guo J-H, El-Sigaby NR, Elliott GT. Intravenous administration of monophosphoryl lipid A (MLA) 24 hours before aortic cross-clamping attenuates myocardial stunning in dogs. J Mol Cell Cardiol 1995;27:A49.
61. Nelson DW, Brown JM, Banerjee A, et al. Pretreatment with a nontoxic derivative of endotoxin induces functional protection against cardiac ischemia/reperfusion injury. Surgery 1991;110:365-369.
62. Zhao L, Kirsch CC, Hagen SR, Elliott GT. Preservation of global cardiac function in the rabbit following protracted ischemia/reperfusion using monophosphoryl lipid A (MLA). J Mol Cell Cardiol 1996;28:197-208.
63. Elliott GT, Kirsch CC, Zhao L. Monophosphoryl lipid A (MLA) in a rabbit model of prolonged regional ischemia and reperfusion induces functional and biochemical cardioprotection. J Mol Cell Cardiol 1995;27:A19.
64. Kida M, Fujiwara H, Ishida M, et al. Ischemic preconditioning preserves creatine phosphate and intracellular pH. Circ Res 1991;84:2595-2603.
65. Murray CE, Richard VJ, Reimer KA, Jennings RB. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ Res 1990;66:913-931.
66. Vuorinen K, Ylitalo K, Peuhkurinen K, Raatikainen P, Ala-Rämi A, Hassinen IE. Mechanisms of ischemic preconditioning in rat myocardium. Circulation 1995;91: 2810-2818.
67. Abel FL. Myocardial function in sepsis and endotoxin shock. Am J Physiol 1989;257:R1265-R1281.
68. Marber MS, Mestril R, CM SH, Sayen MR, Yellon DM. Overexpression of the rat inducible 70-kD heat stress protein in a transgenic mouse increases the resistance of the heart to ischemic injury. J Clin Invest 1995;95:1446-1456.
69. Marber MS, Mestril R, Yellon DM, Dillman WH. A heat shock protein 70 transgene results in myocardial protection. Circulation 1994;90:I536.
70. Qian Y-Z, Kontos MC, Gu Y, Kukreja RC. Quercetin blocks ischemic tolerance in heat stressed rat hearts. Circulation 1994;90:I536.
71. Nichols CG, Lederer WJ. Adenosine triphosphate-sensitive potassium channels in the cardiovascular system. Am J Physiol (Heart Circ Physiol, 30) 1991;26:H1675-H1686.
72. Engelhardt R, Mackensen A, Galanos C, Andreesen R. Biological response to intravenously administered endotoxin in patients with advanced cancer. J Biol Response Mod 1990; 9:480-491.
73. Henricson B, Benjamin WR, Vogel SN. Differential cytokine induction by doses of lipopolysaccharide and monophosphoryl lipid A that result in equivalent early endotoxin tolerance. Infect Immun 1990;58:2429-2437.
74. Shindo T, Ikeda U, Ohkawa F, et al. Nitric oxide synthesis in rat cardiac myocytes and flbroblasts. Life Sci 1994;55: 1101-1108.
75. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993;87:893-899.
76. Gho BC, Schoemaker RG, Van der Lee C, Sharma HS, Verdouw PD. Myocardial infarct size limitation in rat by transient renal ischemia. Circulation 1994;90:I476.
77. Fleming I, Gray GA, Stoclet JC. Inducible but not constitutive production of NO by vascular smooth muscle cells. Eur J Pharmacol 1991;200:375-376.
78. Fleming I, Gray GA, Stoclet JC. Influence of endothelium on induction of the L-arginine-nitric oxide pathway in rat aortas. Am J Physiol 1991;264:H1200-H1207.
79. Rees DD, Cellek S, Palmer MJ, Moncada S. Dexamethasone prevents the induction by endotoxin of a nitric-oxide synthase and the associated effects on vascular tone. An insight into endotoxic shock. Biochem Biophys Commun 1990;173:541-547.
80. Whalley ET, Solomon JA, Modafferi DM, Bonham KA, Cheronis JC. CP-0127, a novel potent bradykinin antagonist, increases survival in rat and rabbit models of endotoxin shock. AAS 38/III. In Recent Progress on Kinins Basel: Birkhauser, p 1992:413-442.
81. Traber DL, Redl H, Schlag G, et al. Cardiopulmonary responses to continuous administration of endotoxin. Am J Physiol (Heart Circ Physiol) 1988;254:H833-H839.
82. Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: A novel hypotensive peptide isolated from human pheochromoeytoma. Biochem Biophys Res Commun 1993; 192:553-560.
83. Sugo S, Minamino N, Shaji H, et al. Interleukin-1, tumor necrosis factor and lipopolysaccharide additively stimulate production of adrenomedullin in vascular smooth muscle cells. Biochem Biophys Res Commun 1995;207:25-32.
84. Pigott J, Garner T, Boone B, Chang JK, Hyman A, Lippton H. Adrenomedullin (ADM): An endogenous coronary (COR) vasodilator peptide. Circulation 1994;90:I257.
85. Yao Z, Foster PA, Gross GJ. Monophosphoryl lipid A protects against endotoxic shock via inhibiting neutrophil infiltration and preventing disseminated intravascular coagulation. Circ Shock 1994;43:107-114.
86. Pogrebniak HW, Matthews W, Pass HI. Alterations in macrophage free radical and tumor necrosis factor production by a potassium channel activator. J Surg Res 1992;52: 395-400.